Developer docs
API playgroundTry for free, no card

Search company profiles

Regenity

Full company profile

uuid003dcp5

Namestring
Regenity
Legal namestring
Collagen Matrix, Inc.
Websiteurl
regenity.com
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Regenity Biosciences is a privately held regenerative medicine company headquartered in Paramus, New Jersey, that designs, manufactures, and supplies bioresorbable medical devices and biomaterials to medical device OEMs and clinicians across eight therapeutic areas: dental, spine, orthopedics, neurosurgery, advanced wound care, sports medicine, ENT, and peripheral nerve repair. Founded in 1997 as Collagen Matrix, Inc. and rebranded in 2023 following the Polyganics acquisition, the company operates from five ISO 13485- and MDSAP-certified manufacturing facilities totaling more than 170,000 square feet across New Jersey and Groningen, Netherlands, producing 5 million+ devices annually for customers in 80+ countries.

Regenity's technology platform spans four core pillars: reconstituted and crosslinked collagen (xenograft), bioceramics and mineral-collagen composites, synthetic bioresorbable polymers, and hybrid polymer-collagen composites, supported by 100+ patents and 170+ regulatory approvals (63 FDA 510(k) clearances, 24 CE marks, 5 China MDRCs). The portfolio includes branded products such as Matrixflex, MatrixDerm, MatrixOss, OssiMend, RejuvaKnee (the first FDA-cleared regenerative meniscal implant), DuraMatrix, Neuroflex, NEUROLAC, NEUROCAP, and LIQOSEAL, alongside custom contract development and manufacturing (CDMO) services delivered on a concept-to-commercialization timeline of under two years.

The company monetizes through two complementary channels: (1) private-label/OEM product sales to medical device companies, where Regenity's proprietary components are rebranded and commercialized by partners, and (2) end-to-end CDMO engagements spanning R&D, regulatory support, process engineering, and commercial-scale manufacturing. Go-to-market is primarily direct enterprise field sales augmented by trade-show presence (MD&M West, MEDICA, Society for Biomaterials). Exclusive arrangements such as the MiMedx manufacturing and supply agreement exemplify the OEM/white-label model. Regenity is controlled by private-equity sponsors Linden Capital Partners (since ~2020) and Cinven (added February 2026).

Short descriptiontext

Regenity Biosciences is a privately held regenerative medicine company that designs, manufactures, and supplies bioresorbable collagen and polymer medical devices, plus end-to-end CDMO services, to medical device OEMs and clinicians across dental, spine, neurosurgery, nerve repair, and wound care.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParamus, United States
HQ citystring
Paramus
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative medical devices, bioresorbable biomaterials, bone graft substitutes, tissue regeneration implants, medical device CDMO
Industry4 codes
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code4 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Dental Equipment and Supplies Manufacturing339114
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
  • Dental Equipment & Supplies3843
Product category
Regenerative Medical Devices
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Private Label Product Sales
TypeOne Time License
Description

Regenity sells its proprietary collagen and polymer-based regenerative medical devices to OEM customers through private label arrangements. Products include dental membranes, bone grafts, dural repair products, nerve repair devices, and orthopedic implants.

regenity.com
2CDMO Services
TypeProfessional Services
Description

Contract Development and Manufacturing services providing end-to-end support from R&D through regulatory, process engineering, and commercial-scale manufacturing. Regenity supports medtech partners from early feasibility through full commercialization.

regenity.com
3Dental Products
TypeOne Time License
Description

Collagen dental membranes, bone graft substitutes, and wound dressings sold to dental device companies and clinicians. Products include Matrix*flex™, MatrixDerm®, MatrixMem™, MatrixOss™, SynOss™, GUIDOR®, and Collatene™.

regenity.com
4Spine & Orthopedic Products
TypeOne Time License
Description

Xenograft mineral and collagen composite matrix bone graft substitutes, resorbable collagen wraps, and meniscal repair implants including RejuvaKnee™, OssiMend®, and TenoMend™.

regenity.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Regenity Biosciences manufactures and sells proprietary bioresorbable medical devices—collagen, mineral, and synthetic polymer-based membranes, bone graft substitutes, dural repair patches, nerve repair conduits, and meniscal implants—primarily as private-label products to medical device OEMs, while also providing end-to-end contract development and manufacturing (CDMO) services for regenerative medical devices from R&D through regulatory clearance and commercial-scale production.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 30M+ patients impacted since founding
+5 more records
Product overview1 text field

Regenity Biosciences is a regenerative medicine company offering a comprehensive portfolio of bioresorbable medical devices for tissue and bone regeneration. The company's product portfolio is organized into four main categories: Dental (collagen dental membranes, bone graft substitutes including Matrix*flex*™, MatrixDerm®, MatrixOss™, SynOss™, GUIDOR®, Collatene™), Dural Repair & Closure (collagen-based dural repair membranes including DuraMatrix® family and LIQOSEAL®), Spine & Orthopedics (bone graft substitutes including OssiMend® family and meniscal repair implant RejuvaKnee™), and Nerve Repair (collagen and synthetic nerve conduits and wraps including Neuroflex®, NEUROLAC®, NEUROCAP®, NeuroMatrix®, NeuroMend, and VIVOSORB®). Regenity also offers end-to-end contract development and manufacturing (CDMO) services for bioresorbable medical devices. The company was founded in 1997 as Collagen Matrix, Inc. and rebranded to Regenity Biosciences in 2022 after acquiring Polyganics. Technology platforms include collagen-derived technologies, bioceramic technologies, biocomposite technologies, and synthetic polymer technologies.

Product and service19 records
1Matrix*flex™
CategoryDental
Description

A strong, regenerative crosslinked collagen dental membrane manufactured from purified porcine peritoneum tissue, used for guided tissue and bone regeneration in dental surgery.

2MatrixDerm® Family
CategoryDental
Description

Regenerative collagen dental membranes, nonfriable matrices, absorbent wound dressings, and membrane caps used for oral surgical repairs, extraction sockets, denture sores, oral ulcers, periodontal surgical wounds, and suture sites.

3MatrixMem™
CategoryDental
Description

A conformable and nonfriable regenerative collagen membrane for dental tissue regeneration procedures.

4MatrixOss™ Granules
CategoryDental
Description

An osteoconductive, porous, anorganic bone mineral derived from porcine cancellous bone, used for dental bone grafting.

5SynOss™ Family
CategoryDental
Description

Osteoconductive calcium phosphate-based bone graft material (granules, plug, and putty forms) offering a synthetic carbonate apatite alternative to human allograft and animal origin bone graft material.

6GUIDOR® Synthetic Bone Graft Products
CategoryDental
Description

100% synthetic bone graft substitute products including GUIDOR® calc-i-oss and GUIDOR® easy-graft that support bone regeneration and provide clot stability during initial healing.

7Collatene™
CategoryDental
Description

An absorbent microfibrillar collagen matrix used for management of oral wounds and sores.

8DuraMatrix® Family
CategoryDural Repair & Closure
Description

Collagen dural repair membranes (DuraMatrix®, DuraMatrix-Onlay®, DuraMatrix-Onlay® Plus, and DuraMatrix® Suturable) designed to optimize conformability and strength with high CSF leak resistance for cranial dural closure.

9LIQOSEAL®
CategoryDural Repair & Closure
Description

A dural sealant used as an adjunct to standard methods of cranial dural repair to provide a watertight closure of the dura mater and reduce CSF leakage.

10RejuvaKnee™ Meniscal Repair Implant
CategorySpine & Orthopedics
Description

A natural bovine-derived collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus; the first and only FDA-cleared regenerative implant device for meniscal repair.

11OssiMend® Bioactive Bone Graft Line
CategorySpine & Orthopedics
Description

Bioactive biocomposite matrices (moldable pucks, strips, pads, blocks, and putties) that are highly absorbent, flexible, compression-resistant, retain stem cells, and resorb during bone remodeling.

12TenoMend™
CategorySpine & Orthopedics
Description

A resorbable type I collagen matrix that provides a non-constricting encasement for injured tendons in tendon repair procedures.

13Neuroflex® Nerve Conduit
CategoryNerve Repair
Description

A flexible, collagen-based, kink-resistant nerve conduit ideal for reconstruction across nerve gaps spanning joints.

14NEUROLAC® Nerve Guide
CategoryNerve Repair
Description

Synthetic nerve guides indicated for reconstruction of peripheral nerve discontinuities up to 20 mm.

15NEUROCAP® Nerve Capping Device
CategoryNerve Repair
Description

A synthetic capping device intended for the surgical management of symptomatic end-neuromas.

16NeuroMatrix® Nerve Conduit
CategoryNerve Repair
Description

A collagen-based conduit that alleviates tension at the repair site in straight gap peripheral nerve repair locations.

17NeuroMend Nerve Wrap
CategoryNerve Repair
Description

A nerve wrap ideal for crush or compression injuries or partially severed nerves.

18VIVOSORB® Adhesion Prevention Film
CategoryNerve Repair
Description

A flexible bioresorbable synthetic polymer film that separates opposing soft tissues post-surgery to prevent scar tissue and unintended adhesions.

19Regenerative Medical Device CDMO Services
CategoryCDMO Services
Description

End-to-end contract development and manufacturing organization (CDMO) services providing R&D, material processing, prototype development, regulatory support, and commercial-scale manufacturing for regenerative medical devices, serving medtech partners from early feasibility through full commercialization.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-03-01
Description

In March 2024, MiMedx Group entered into an exclusive manufacturing and supply agreement with Regenity Biosciences, granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-10-05
Description

Collagen Matrix (now Regenity) acquired Polyganics, a medical technology company specializing in synthetic polymer bioresorbable devices. The acquisition expanded Regenity's portfolio to include ENT and general surgery products while strengthening neurosurgery and peripheral nerve offerings. Polyganics' 75 employees joined Regenity.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Collagen Matrix acquired Sunstar's Degradable Solutions division including the GUIDOR synthetic bone graft and membrane business. GUIDOR's synthetic technologies complement Collagen Matrix's proprietary collagen-based products, enabling a comprehensive regenerative medicine portfolio.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

GT Medical Technologies partnered with Regenity to bring GammaTile - a breakthrough in brain tumor treatment - to patients who need it most. Regenity's partnership supports the design and manufacturing of GammaTile therapy.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss private company and the dominant global player in dental bone graft substitutes and barrier membranes (Bio-Oss, Bio-Gide) — the direct incumbent Regenity benchmarks its MatrixOss and Matrixflex products against in clinical studies.

TypeBroad incumbent
Description

Large diversified medtech incumbent with orthopedics, spine, and surgical equipment portfolios that overlap Regenity's spine/orthopedic and ENT segments — competes broadly but does not specialize in collagen/synthetic-polymer regenerative biomaterials at Regenity's scale.

TypeDirect peer
Description

Public regenerative medical device company with overlapping portfolios in dural repair (DuraGen), nerve repair (NeuraGen, AxoGen-adjacent), and collagen-based wound matrices — directly comparable product categories in neurosurgery and nerve repair to Regenity's DuraMatrix and Neuroflex lines.

TypeDirect peer
Description

Public regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications — Regenity's exclusive supply partner for collagen wound dressings under a March 2024 agreement, making it both customer and competitive comparable.

TypeDirect peer
Description

Division of dsm-firmenich that supplies biomedical materials, including collagen, bioresorbable polymers, and coatings to the medical device industry — a directly comparable biomaterials CDMO/input supplier serving many of the same medtech OEMs.

TypeDirect peer
Description

Israel-based regenerative medicine company developing recombinant human collagen and regenerative tissue products for orthopedics, wound care, and 3D bioprinting — a closely comparable biomaterials platform with similar collagen-derived technology focus.

TypeDirect peer
Description

Public commercial-stage regenerative medicine company selling MACI (autologous chondrocyte implant for cartilage repair) and Epicel — comparable as a pure-play regenerative medicine business selling into orthopedics and wound care channels.

TypeDirect peer
Description

Nonprofit tissue bank that develops and distributes allograft and regenerative tissue products for orthopedics, wound care, and sports medicine — a directly comparable regenerative biologics platform serving the same end markets.

TypeBroad incumbent
Description

Diversified medical products incumbent with surgical solutions, hemostats, and regenerative tissue products (e.g., Tisseel, Coseal) — broad incumbent that overlaps Regenity's surgical sealant (LIQOSEAL) and adhesion prevention (VIVOSORB) franchises.

TypeDirect peer
Description

Public regenerative medicine company focused on advanced wound care and surgical biologics (Apligraf, Dermagraft, NuShield) — directly comparable in wound care biologics and regenerative product positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment8 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Regenity

Regenerative Medical Devicesregenity.com

Regenity Biosciences is a privately held regenerative medicine company that designs, manufactures, and supplies bioresorbable collagen and polymer medical devices, plus end-to-end CDMO services, to medical device OEMs and clinicians across dental, spine, neurosurgery, nerve repair, and wound care.

What Regenity does

Regenity Biosciences is a privately held regenerative medicine company headquartered in Paramus, New Jersey, that designs, manufactures, and supplies bioresorbable medical devices and biomaterials to medical device OEMs and clinicians across eight therapeutic areas: dental, spine, orthopedics, neurosurgery, advanced wound care, sports medicine, ENT, and peripheral nerve repair. Founded in 1997 as Collagen Matrix, Inc. and rebranded in 2023 following the Polyganics acquisition, the company operates from five ISO 13485- and MDSAP-certified manufacturing facilities totaling more than 170,000 square feet across New Jersey and Groningen, Netherlands, producing 5 million+ devices annually for customers in 80+ countries.

Regenity's technology platform spans four core pillars: reconstituted and crosslinked collagen (xenograft), bioceramics and mineral-collagen composites, synthetic bioresorbable polymers, and hybrid polymer-collagen composites, supported by 100+ patents and 170+ regulatory approvals (63 FDA 510(k) clearances, 24 CE marks, 5 China MDRCs). The portfolio includes branded products such as Matrixflex, MatrixDerm, MatrixOss, OssiMend, RejuvaKnee (the first FDA-cleared regenerative meniscal implant), DuraMatrix, Neuroflex, NEUROLAC, NEUROCAP, and LIQOSEAL, alongside custom contract development and manufacturing (CDMO) services delivered on a concept-to-commercialization timeline of under two years.

The company monetizes through two complementary channels: (1) private-label/OEM product sales to medical device companies, where Regenity's proprietary components are rebranded and commercialized by partners, and (2) end-to-end CDMO engagements spanning R&D, regulatory support, process engineering, and commercial-scale manufacturing. Go-to-market is primarily direct enterprise field sales augmented by trade-show presence (MD&M West, MEDICA, Society for Biomaterials). Exclusive arrangements such as the MiMedx manufacturing and supply agreement exemplify the OEM/white-label model. Regenity is controlled by private-equity sponsors Linden Capital Partners (since ~2020) and Cinven (added February 2026).

Regenity firmographics

Firmographics
Name
Regenity
Legal name
Collagen Matrix, Inc.
Website
https://regenity.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
101–250 employees
Short description
Regenity Biosciences is a privately held regenerative medicine company that designs, manufactures, and supplies bioresorbable collagen and polymer medical devices, plus end-to-end CDMO services, to medical device OEMs and clinicians across dental, spine, neurosurgery, nerve repair, and wound care.
Ownership category
akta.pro rank

Regenity industry classification

Industry
Product category
Regenerative Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Dental Equipment and Supplies Manufacturing (339114), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841), Dental Equipment & Supplies (3843)
akta.pro industry
PRIMARYHLAAAGAH
Cartilage, Bone & Musculoskeletal Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Regenerative medical devices
  • Bioresorbable biomaterials
  • Bone graft substitutes
  • Tissue regeneration implants
  • Medical device CDMO

Where Regenity is headquartered

Location

Headquarters

HQ city
Paramus
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Regenity business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Private Label Product Sales: Regenity sells its proprietary collagen and polymer-based regenerative medical devices to OEM customers through private label arrangements. Products include dental membranes, bone grafts, dural repair products, nerve repair devices, and orthopedic implants.
  2. CDMO Services: Contract Development and Manufacturing services providing end-to-end support from R&D through regulatory, process engineering, and commercial-scale manufacturing. Regenity supports medtech partners from early feasibility through full commercialization.
  3. Dental Products: Collagen dental membranes, bone graft substitutes, and wound dressings sold to dental device companies and clinicians. Products include Matrix*flex™, MatrixDerm®, MatrixMem™, MatrixOss™, SynOss™, GUIDOR®, and Collatene™.
  4. Spine & Orthopedic Products: Xenograft mineral and collagen composite matrix bone graft substitutes, resorbable collagen wraps, and meniscal repair implants including RejuvaKnee™, OssiMend®, and TenoMend™.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels9 records

Regenity product offering

Product offering

Core offering

Regenity Biosciences manufactures and sells proprietary bioresorbable medical devices—collagen, mineral, and synthetic polymer-based membranes, bone graft substitutes, dural repair patches, nerve repair conduits, and meniscal implants—primarily as private-label products to medical device OEMs, while also providing end-to-end contract development and manufacturing (CDMO) services for regenerative medical devices from R&D through regulatory clearance and commercial-scale production.

Product overview

Regenity Biosciences is a regenerative medicine company offering a comprehensive portfolio of bioresorbable medical devices for tissue and bone regeneration. The company's product portfolio is organized into four main categories: Dental (collagen dental membranes, bone graft substitutes including Matrix*flex*™, MatrixDerm®, MatrixOss™, SynOss™, GUIDOR®, Collatene™), Dural Repair & Closure (collagen-based dural repair membranes including DuraMatrix® family and LIQOSEAL®), Spine & Orthopedics (bone graft substitutes including OssiMend® family and meniscal repair implant RejuvaKnee™), and Nerve Repair (collagen and synthetic nerve conduits and wraps including Neuroflex®, NEUROLAC®, NEUROCAP®, NeuroMatrix®, NeuroMend, and VIVOSORB®). Regenity also offers end-to-end contract development and manufacturing (CDMO) services for bioresorbable medical devices. The company was founded in 1997 as Collagen Matrix, Inc. and rebranded to Regenity Biosciences in 2022 after acquiring Polyganics. Technology platforms include collagen-derived technologies, bioceramic technologies, biocomposite technologies, and synthetic polymer technologies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Matrix*flex™ A strong, regenerative crosslinked collagen dental membrane manufactured from purified porcine peritoneum tissue, used for guided tissue and bone regeneration in dental surgery.
  • MatrixDerm® Family Regenerative collagen dental membranes, nonfriable matrices, absorbent wound dressings, and membrane caps used for oral surgical repairs, extraction sockets, denture sores, oral ulcers, periodontal surgical wounds, and suture sites.
  • MatrixMem™ A conformable and nonfriable regenerative collagen membrane for dental tissue regeneration procedures.
  • MatrixOss™ Granules An osteoconductive, porous, anorganic bone mineral derived from porcine cancellous bone, used for dental bone grafting.
  • SynOss™ Family Osteoconductive calcium phosphate-based bone graft material (granules, plug, and putty forms) offering a synthetic carbonate apatite alternative to human allograft and animal origin bone graft material.
  • GUIDOR® Synthetic Bone Graft Products 100% synthetic bone graft substitute products including GUIDOR® calc-i-oss and GUIDOR® easy-graft that support bone regeneration and provide clot stability during initial healing.
  • Collatene™ An absorbent microfibrillar collagen matrix used for management of oral wounds and sores.
  • DuraMatrix® Family Collagen dural repair membranes (DuraMatrix®, DuraMatrix-Onlay®, DuraMatrix-Onlay® Plus, and DuraMatrix® Suturable) designed to optimize conformability and strength with high CSF leak resistance for cranial dural closure.
  • LIQOSEAL® A dural sealant used as an adjunct to standard methods of cranial dural repair to provide a watertight closure of the dura mater and reduce CSF leakage.
  • RejuvaKnee™ Meniscal Repair Implant A natural bovine-derived collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus; the first and only FDA-cleared regenerative implant device for meniscal repair.
  • OssiMend® Bioactive Bone Graft Line Bioactive biocomposite matrices (moldable pucks, strips, pads, blocks, and putties) that are highly absorbent, flexible, compression-resistant, retain stem cells, and resorb during bone remodeling.
  • TenoMend™ A resorbable type I collagen matrix that provides a non-constricting encasement for injured tendons in tendon repair procedures.
  • Neuroflex® Nerve Conduit A flexible, collagen-based, kink-resistant nerve conduit ideal for reconstruction across nerve gaps spanning joints.
  • NEUROLAC® Nerve Guide Synthetic nerve guides indicated for reconstruction of peripheral nerve discontinuities up to 20 mm.
  • NEUROCAP® Nerve Capping Device A synthetic capping device intended for the surgical management of symptomatic end-neuromas.
  • NeuroMatrix® Nerve Conduit A collagen-based conduit that alleviates tension at the repair site in straight gap peripheral nerve repair locations.
  • NeuroMend Nerve Wrap A nerve wrap ideal for crush or compression injuries or partially severed nerves.
  • VIVOSORB® Adhesion Prevention Film A flexible bioresorbable synthetic polymer film that separates opposing soft tissues post-surgery to prevent scar tissue and unintended adhesions.
  • Regenerative Medical Device CDMO Services End-to-end contract development and manufacturing organization (CDMO) services providing R&D, material processing, prototype development, regulatory support, and commercial-scale manufacturing for regenerative medical devices, serving medtech partners from early feasibility through full commercialization.

Quantifiable outcome

  • 30M+ patients impacted since founding
  • +5 more outcomes

Companies that use Regenity

Customer profile

Named customers1 record

Segments8 records

Ideal customer profiles3 records

Regenity technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

Regenity partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • MiMedx GroupcoreOEM/ Whitelabel/ Licensing Partner · 1 March 2024In March 2024, MiMedx Group entered into an exclusive manufacturing and supply agreement with Regenity Biosciences, granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications.
  • PolyganicscoreStrategic or Co-development Partner · 5 October 2022Collagen Matrix (now Regenity) acquired Polyganics, a medical technology company specializing in synthetic polymer bioresorbable devices. The acquisition expanded Regenity's portfolio to include ENT and general surgery products while strengthening neurosurgery and peripheral nerve offerings. Polyganics' 75 employees joined Regenity.
  • Sunstar / GUIDORcoreStrategic or Co-development Partner · 1 January 2020Collagen Matrix acquired Sunstar's Degradable Solutions division including the GUIDOR synthetic bone graft and membrane business. GUIDOR's synthetic technologies complement Collagen Matrix's proprietary collagen-based products, enabling a comprehensive regenerative medicine portfolio.
  • GT Medical TechnologiescoreStrategic or Co-development PartnerGT Medical Technologies partnered with Regenity to bring GammaTile - a breakthrough in brain tumor treatment - to patients who need it most. Regenity's partnership supports the design and manufacturing of GammaTile therapy.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Regenity competitors and assessment

Company assessment

Direct peers

  • Geistlich Pharma: Swiss private company and the dominant global player in dental bone graft substitutes and barrier membranes (Bio-Oss, Bio-Gide) — the direct incumbent Regenity benchmarks its MatrixOss and Matrixflex products against in clinical studies.
  • Integra LifeSciences: Public regenerative medical device company with overlapping portfolios in dural repair (DuraGen), nerve repair (NeuraGen, AxoGen-adjacent), and collagen-based wound matrices — directly comparable product categories in neurosurgery and nerve repair to Regenity's DuraMatrix and Neuroflex lines.
  • MiMedx Group: Public regenerative medicine company selling placental tissue allografts (EpiFix, AmnioFix) for wound care and surgical applications — Regenity's exclusive supply partner for collagen wound dressings under a March 2024 agreement, making it both customer and competitive comparable.
  • DSM Biomedical (dsm-firmenich): Division of dsm-firmenich that supplies biomedical materials, including collagen, bioresorbable polymers, and coatings to the medical device industry — a directly comparable biomaterials CDMO/input supplier serving many of the same medtech OEMs.
  • CollPlant Biotechnologies: Israel-based regenerative medicine company developing recombinant human collagen and regenerative tissue products for orthopedics, wound care, and 3D bioprinting — a closely comparable biomaterials platform with similar collagen-derived technology focus.
  • Vericel: Public commercial-stage regenerative medicine company selling MACI (autologous chondrocyte implant for cartilage repair) and Epicel — comparable as a pure-play regenerative medicine business selling into orthopedics and wound care channels.
  • MTF Biologics: Nonprofit tissue bank that develops and distributes allograft and regenerative tissue products for orthopedics, wound care, and sports medicine — a directly comparable regenerative biologics platform serving the same end markets.
  • Organogenesis: Public regenerative medicine company focused on advanced wound care and surgical biologics (Apligraf, Dermagraft, NuShield) — directly comparable in wound care biologics and regenerative product positioning.

Broad incumbents

  • Stryker: Large diversified medtech incumbent with orthopedics, spine, and surgical equipment portfolios that overlap Regenity's spine/orthopedic and ENT segments — competes broadly but does not specialize in collagen/synthetic-polymer regenerative biomaterials at Regenity's scale.
  • Baxter International: Diversified medical products incumbent with surgical solutions, hemostats, and regenerative tissue products (e.g., Tisseel, Coseal) — broad incumbent that overlaps Regenity's surgical sealant (LIQOSEAL) and adhesion prevention (VIVOSORB) franchises.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Regenity social profiles

Digital presence

Regenity compliance and trust

Trust signal

Compliance6 records

Regenity financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Regenity leadership team

Management profile

Number of profiles

Profiles10 records

Regenity subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Regenity funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Regenity M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Regenity

What does Regenity do?

Regenity Biosciences manufactures and sells proprietary bioresorbable medical devices—collagen, mineral, and synthetic polymer-based membranes, bone graft substitutes, dural repair patches, nerve repair conduits, and meniscal implants—primarily as private-label products to medical device OEMs, while also providing end-to-end contract development and manufacturing (CDMO) services for regenerative medical devices from R&D through regulatory clearance and commercial-scale production.

Is Regenity a public or private company?

Regenity is a private company. It is classified as private equity controlled and is currently operating.

When was Regenity founded?

Regenity was founded in 1997. It employs 101 to 250 people.

Where is Regenity based?

Regenity is headquartered in Paramus, United States, in the North America region.

How does Regenity make money?

Four revenue lines are on record. Private Label Product Sales are the primary driver. The others are CDMO Services, dental Products and spine & Orthopedic Products.

Who are Regenity's main competitors?

Direct peers on record are Geistlich Pharma, Integra LifeSciences, MiMedx Group, DSM Biomedical (dsm-firmenich), CollPlant Biotechnologies, Vericel, MTF Biologics and Organogenesis. Broad incumbents are Stryker and Baxter International.

Does Regenity have an API?

No public API is recorded for Regenity.

What industry is Regenity in?

Regenity's product category is Regenerative Medical Devices. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comMarket Trend Analysis: The Impact of Recent Advances on the Nerve Repair and Regenerative MarketThe nerve repair and regenerative market is projected to grow to $19.1 billion by 2030, driven by a compound annual growth rate of 11.9%, fueled by advancements in biomaterials, neuromodulation technologies, stem cell therapies, and increasing investments in nerve regeneration research. In March 2024, MiMedx Group entered into an exclusive manufacturing and supply agreement with Regenity Biosciences, granting MiMedx commercialization rights to a 510(k)-cleared bovine-derived collagen matrix product for advanced wound care and surgical applications. The article also notes that UK-based Surtex Instruments launched the infinex series of microsurgery tools in November 2023, featuring diamond-dusted technology for improved surgical precision in nerve repair procedures.PR NewswireRegenity Biosciences Marks 63rd FDA 510(k) Clearance with Expansion of Neurosurgical PortfolioRegenity Biosciences announced its 63rd FDA 510(k) clearance for DuraMatrix® Repair, a resorbable collagen membrane for dural repair during neurosurgery. The product, composed of Type I and Type III bovine collagen, provides high mechanical strength and conformability to support optimal surgical outcomes. The clearance reinforces Regenity's regulatory track record and expands its neurosurgical portfolio.GlobeNewswireAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityAVITA Medical launched Cohealyx, a collagen-based dermal matrix, in the U.S. on April 3, 2025, co-developed with Regenity Biosciences. The product aims to speed wound bed preparation, with pre-clinical data showing graft readiness as early as 7 days. The company is enrolling participants in the Cohealyx I trial to evaluate clinical outcomes.ReutersTransforming the future of regenerative medicineRegenity leverages its customized product development process and off-the-shelf product portfolio to help CDMOs and medtech companies reduce development timelines and accelerate market entry. The company offers FDA-cleared solutions like RejuvaKnee™, a collagen-based implant that facilitates tissue regeneration rather than surgical replacement.Ortho Spine NewsRegenity Biosciences Receives 510(k) Clearance for RejuvaKnee™, a Groundbreaking Regenerative Meniscus Implant Device to Redefine the Standard of CareRegenity Biosciences received FDA 510(k) clearance for RejuvaKnee, a collagen-based meniscal implant for meniscus repair. The device is estimated to have a market value of over $900 million, and Regenity is exploring strategic partnerships for U.S. commercialization.YahooRegenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in China After First-of-its-Kind Breakthrough Clinical StudyRegenity Biosciences received NMPA approval for its crosslinked collagen dental membrane in China, following a Level 1 randomized study of 174 patients. The study showed Matrixflex™ outperformed Geistlich Bio-Gide in periodontal outcomes. The company plans to commercialize the product via partnerships.PR NewswireRegenity Biosciences Receives Regulatory Approval for Collagen Dental Membrane in China After First-of-its-Kind Breakthrough Clinical StudyRegenity Biosciences received NMPA approval in China for its crosslinked collagen dental membrane, Matrixflex, after a Level 1 clinical study. The study of 174 patients found Matrixflex superior to Geistlich Bio-Gide in periodontal outcomes. The company plans to commercialize the product via partnerships.GlobeNewswireAVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound CareAVITA Medical entered an exclusive multi-year agreement with Regenity Biosciences to develop and distribute a collagen-based dermal matrix. Regenity expects 510(k) clearance in Q4 2024, with AVITA paying $2M upon clearance and up to $3M later. AVITA plans clinical studies in 2025 to establish a one-stage closure standard of care.YahooAVITA Medical Expands Portfolio with Unique Dermal Matrix to Advance Wound CareAVITA Medical signed an exclusive multi-year agreement with Regenity Biosciences to commercialize a collagen-based dermal matrix, with Regenity expected to obtain 510(k) clearance in Q4 2024. AVITA will pay $2 million upon clearance and up to $3 million later, with revenue sharing rising from 50% to 60%.